Bio

Clinical Focus


  • Sleep Medicine

Education & Certifications


  • Fellowship:UCLA Harbor Pulmonary Disease and Critical Care Fellowship (1982) CA
  • Residency:University of Toronto (1980) Canada
  • Residency:University of Toronto (1979) Canada
  • Medical Education:University of Ottawa School of Medicine (1977) Canada
  • Board Certification: Sleep Medicine, American Board of Sleep Medicine (1988)
  • Board Certification: Pulmonary Disease, American Board of Internal Medicine (1982)
  • Board Certification: Internal Medicine, American Board of Internal Medicine (1980)

Publications

All Publications


  • Contemporary Challenges and Strategies for Improving Outcomes for Patients With Restless Legs Syndrome AMERICAN JOURNAL OF MANAGED CARE Buchfuhrer, M. J. 2012; 18 (12): S283-S290

    Abstract

    Restless legs syndrome (RLS) is a common neurological disease that is diagnosed solely based on clinical symptoms and may be treated via both nonpharmacologic and pharmacologic means. Despite its somewhat trivial-sounding name, this disease has a very significant impact upon the lives of RLS patients and imposes a substantial burden, as evidenced by direct and indirect costs and loss of productivity. After the introduction of US Food and Drug Administration (FDA)- approved drugs for the management of RLS in 2005, there has been an increase in the awareness of the disease. Increased awareness of RLS has resulted in a greater number of patients receiving treatment for RLS, and in turn, more patients presenting with refractory RLS, in part due to drug-emergent issues such as augmentation. Furthermore, management of the disease is still not optimal. Barriers to obtaining adequate treatment include healthcare providers' lack of knowledge, limited availability of specialists who can provide care to patients presenting with refractory RLS, and access to and cost of medications. Opportunities for managed care to enhance the recognition and treatment of RLS are discussed, with suggestions for improving outcomes in patients with RLS.

    View details for Web of Science ID 000312227100001

    View details for PubMedID 23327482

  • Strategies for the Treatment of Restless Legs Syndrome NEUROTHERAPEUTICS Buchfuhrer, M. J. 2012; 9 (4): 776-790

    Abstract

    Restless legs syndrome (RLS) is a common neurological disorder of unknown etiology that is managed by therapy directed at relieving its symptoms. Treatment of patients with milder symptoms that occur intermittently may be treated with nonpharmacological therapy but when not successful, drug therapy should be chosen based on the timing of the symptoms and the needs of the patient. Patients with moderate to severe RLS typically require daily medication to control their symptoms. Although the dopamine agonists, ropinirole and pramipexole have been the drugs of choice for patients with moderate to severe RLS, drug emergent problems like augmentation may limit their use for long term therapy. Keeping the dopamine agonist dose as low as possible, using longer acting dopamine agonists such as the rotigotine patch and maintaining a high serum ferritin level may help prevent the development of augmentation. The α2δ anticonvulsants may now also be considered as drugs of choice for moderate to severe RLS patients. Opioids should be considered for RLS patients, especially for those who have failed other therapies since they are very effective for severe cases. When monitored appropriately, they can be very safe and durable for long term therapy. They should also be strongly considered for treating patients with augmentation as they are very effective for relieving the worsening symptoms that occur when decreasing or eliminating dopamine agonists.

    View details for DOI 10.1007/s13311-012-0139-4

    View details for Web of Science ID 000310325000009

    View details for PubMedID 22923001